Pertuzumab, a recombinant monoclonal antibody to HER2 that binds to a different domain of the receptor compared with that targeted by trastuzumab, was also shown to prolong survival in HER2-positive breast cancer when added to trastuzumab plus chemotherapy [20]. This evidence concerns the gene ERBB2 and breast carcinoma.